H.C. Wainwright Reiterates Buy Ratings for CRISPR and Gain Therapeutics

Investment firm H.C. Wainwright has maintained its buy rating on the stock of both CRISPR Therapeutics and Gain Therapeutics. The analysts cited strong growth potential within the gene therapy sector to support the positive outlook.